PHARMACEUTICAL COMPOSITION

The invention relates to pharmaceutical compositions comprising an ester of olmesartan, such as olmesartan medoxomil. Olmesartan medoxomil is a prodrug that is hydrolyzed during absorption, but it is not desirable that it hydrolyzes prior to ingestion, during storage. A stable formulation comprising an ester of olmesartan and stearic acid, exhibiting exceptional stability when subject to stress conditions, is disclosed. Processes for the preparation of such pharmaceutical compositions, as well as the use of stearic acid to prevent degradation of olmesartan medoxornil to olmesartan acid in a pharmaceutical composition, are also disclosed. La présente invention concerne une formule stable d'olmésartan medoxomil qui présente une stabilité exceptionnelle lorsqu'elle est soumise à des contraintes.